BioNTech SE - ADR

-2.26 (-0.79%)
Products, Strategic Combinations, Expansion

Pfizer And BioNTech Sign LOI With Biovac Institute

Published: 07/21/2021 11:23 GMT
BioNTech SE - ADR (BNTX) - Pfizer and Biontech Sign Letter of Intent With Biovac Institute to Manufacture Covid-19 Vaccine for Distribution Within African Union.
Pfizer - Biovac to Perform Manufacturing, Distribution Activities Within Co, Biontech’s Global Covid-19 Vaccine Supply Chain Network.
Pfizer - to Facilitate Biovac’s Involvement, Technical Transfer, On-site Development, Equipment Installation Activities to Begin Immediately.
Pfizer - With New Biovac Site Addition, Global Pfizer-biontech Covid-19 Vaccine Supply Chain to Now Include More Than 20 Facilities.
Pfizer - Expects Biovac’s Cape Town Facility Will Be Brought Into Vaccine Supply Chain by End of 2021.
Pfizer - Biovac to Obtain Drug Substance From Facilities in Europe, Manufacturing of Finished Doses to Commence in 2022.
Pfizer - at Full Operational Capacity, Annual Production at Biovac’s Cape Town Facility Will Exceed 100 Million Finished Doses Annually.